NASDAQ · STOCK
Biogen
$202.89
52W $124.56 – $219.72
58/100
$29.99B
35.7
0.16
Is BIIB Bullish or Bearish?
Mixed.
Innellis AI committee rates Biogen (BIIB) Watch with a composite score of 58/100
, based on 6 analysts with 50% agreement.
Last updated July 31, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +1.54 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -18.46 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- EPS declining -8.1% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of July 31, 2026
Overall Committee Score
58/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 19%
of 93 Healthcare peers
Value Analyst
bullish
70
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.4x is a discount to asset value
Growth Analyst
neutral
44
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− EPS declining -8.1% YoY despite any revenue growth
Technical Analyst
bullish
68
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
Macro Analyst
neutral
58
/ 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 44 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Investment Thesis Evolution
Committee score moved marginally from 59.4 to 58.5.
- Conviction changed from moderate to contested.
- Committee agreement fell notably from 67% to 50%.
- New bearish signals: 2 appeared.
- Bullish support removed: 1 signal(s) disappeared.
- New bullish signals: 2 appeared.
- Bearish pressure eased: 2 signal(s) disappeared.
- Analyst(s) changed stance: Macro Analyst.
Analyst-level changes:
- Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
- News Analyst: +1 bullish signal(s).
- Portfolio Manager: +2 bearish signal(s).
Comparing 2026-07-30 to 2026-07-31 (1 day apart).
Technical Analysis
RSI (14)
48.3
Neutral
MACD Histogram
0.154
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$197.00
Resistance
$205.76
Bollinger %B
0.51
Inside Bands
Price vs Moving Averages
EMA 9
$204.22
Below
EMA 21
$203.36
Below
EMA 50
$200.32
Above
EMA 200
$184.22
Above
Fundamental Analysis
Valuation
72
Growth
55
Profitability
0
Financial Health
94
Cash Flow
38
Valuation
P/E Ratio
35.7×
P/B Ratio
1.59×
PEG Ratio
-0.78
Dividend Yield
0.00%
52W High
$219.72
52W Low
$124.56
Quality & Growth
ROE
7.1%
ROA
4.4%
Gross Margin
67.7%
Operating Margin
12.8%
Revenue Growth YoY
—
Debt / Equity
0.44
AI Fundamental Assessment
P/E ratio of 35.7 (rich relative to a 15-40x range); Price-to-book of 1.6x; PEG ratio of -0.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.0%; Net margin of 0.1%; Gross margin of 0.7%; Current ratio of 1.87 (healthy short-term liquidity); Debt-to-equity of 0.44; Free cash flow margin of 1.0% (thin cash generation); Free cash flow per share is positive (20.10); Most recent quarter beat estimates by 19.8%; 5 consecutive earnings beats; EPS growth decelerating (+79.4% -> +0.8% QoQ); Average YoY EPS growth of -34.2%; Analyst estimates rising over recent quarters
Get the Full BIIB Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →